Literature DB >> 8474272

Paraneoplastic syndromes associated with lung cancer.

A M Patel1, D G Davila, S G Peters.   

Abstract

Paraneoplastic phenomena associated with primary lung cancer have diverse initial manifestations and epitomize the systemic nature of human malignant disease. The spectrum of clinical features in patients with paraneoplastic syndromes ranges from mild systemic or cutaneous disease to hypercoagulability and severe neuromyopathic disorders. Although the diagnosis is often one of exclusion, an improved understanding of the pathogenesis involved in some of these syndromes has provided another means of recognizing the disorders and perhaps treating the affected patients. Proposed mechanisms of paraneoplastic processes include the aberrant release of humoral mediators such as hormones and hormone-like peptides, cytokines, and antibodies. In this update, we review the potential mechanisms, diagnosis, and treatment of paraneoplastic syndromes associated with lung cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8474272     DOI: 10.1016/s0025-6196(12)60050-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

Review 1.  Paraneoplastic syndrome in neuroophthalmology.

Authors:  Longdan Kang; Chao Wan
Journal:  J Neurol       Date:  2022-07-02       Impact factor: 6.682

2.  Isolated knee monoarthritis heralding resectable non-small-cell lung cancer. A paraneoplastic syndrome not previously described.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Daniela Chindamo; Michele Bertoni; Emanuele Cassarà; Carlo Salvarani
Journal:  Ann Rheum Dis       Date:  2007-09-03       Impact factor: 19.103

3.  Myasthenia gravis-like syndrome presenting as a component of the paraneoplastic syndrome of lung adenocarcinoma in a nonsmoker.

Authors:  Sahar Eivaz-Mohammadi; Fernando Gonzalez-Ibarra; Hesam Hekmatjou; Rao Mikkilineni; Amit Patel; Amer K Syed
Journal:  Case Rep Oncol Med       Date:  2014-07-23

4.  Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6.

Authors:  Y Tatsumi; H Arioka; S Ikeda; H Fukumoto; K Miyamoto; K Fukuoka; Y Ohe; N Saijo; K Nishio
Journal:  Jpn J Cancer Res       Date:  2001-07

5.  Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study.

Authors:  Montserrat Miret; Erzsébet Horváth-Puhó; Anouk Déruaz-Luyet; Henrik Toft Sørensen; Vera Ehrenstein
Journal:  PLoS One       Date:  2017-08-02       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.